Chronic hives are itchy, raised welts that come and go for more than six weeks. They often appear without a clear trigger and can be exhausting, embarrassing, and disruptive to daily life and sleep. Most cases are not caused by allergy. Effective treatments exist that can stop hives entirely in the majority of patients.
Chronic Spontaneous Urticaria — CSU — is defined as urticaria (hives) persisting longer than six weeks without an identifiable external trigger. The hives may appear at any time of day, last hours, fade, and return in different locations. Some patients also experience deeper swelling (angioedema) of the lips, eyelids, or hands.
Despite its name, chronic urticaria is not usually a classic allergy. The condition is increasingly understood to be an autoimmune-driven mast cell activation disorder, with antibodies in many patients targeting either IgE itself or its receptor on mast cells. Identifying allergic triggers is rarely fruitful; the right approach focuses on suppressing the inflammatory pathway.
Diagnosis is primarily clinical. A detailed history establishes the duration, pattern, and severity of hives, and rules out physical urticaria triggers (cold, pressure, exercise, sunlight). Routine labs typically include CBC, ESR or CRP, thyroid function and antibody testing, and total IgE. Skin biopsy is performed when atypical features suggest urticarial vasculitis.
Urticaria activity scoring (UAS7) is used to track severity and response to treatment objectively. Most patients do not need extensive workup; the diagnosis is straightforward and the focus moves quickly to treatment.
Treatment follows a stepwise approach. First-line therapy is a second-generation H1 antihistamine at standard dose. If hives persist, the antihistamine is titrated upward — frequently to two, three, or four times the standard dose. This relieves symptoms in many patients.
For patients who continue to have significant hives despite high-dose antihistamines, the biologic omalizumab (Xolair) is FDA-approved for chronic spontaneous urticaria. Many patients on Xolair experience substantial reduction in hive activity, and some achieve near-complete resolution. Individual response varies; newer agents and additional biologic options are available for patients who do not respond adequately.
A first visit takes a complete history, reviews the antihistamines tried so far, performs basic screening labs, and outlines a treatment plan. Most patients leave with a clear stepwise approach and an understanding of what success will look like. For patients moving to biologic therapy, prior authorization is handled in-house.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes and does not substitute for clinical judgment or direct medical advice. Treatment decisions are individualized based on your full history, examination, and laboratory findings. If you have an emergency, call 911.